Zhejiang Jolly Pharmaceutical Co Ltd (300181) - Total Assets
Based on the latest financial reports, Zhejiang Jolly Pharmaceutical Co Ltd (300181) holds total assets worth CN¥4.64 Billion CNY (≈ $679.46 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 300181 total equity for net asset value and shareholders' equity analysis.
Zhejiang Jolly Pharmaceutical Co Ltd - Total Assets Trend (2007–2024)
This chart illustrates how Zhejiang Jolly Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Zhejiang Jolly Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Jolly Pharmaceutical Co Ltd's total assets of CN¥4.64 Billion consist of 54.6% current assets and 45.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.2% |
| Accounts Receivable | CN¥801.52 Million | 20.1% |
| Inventory | CN¥523.75 Million | 13.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥92.26 Million | 2.3% |
| Goodwill | CN¥130.32 Million | 3.3% |
Asset Composition Trend (2007–2024)
This chart illustrates how Zhejiang Jolly Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300181 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Jolly Pharmaceutical Co Ltd's current assets represent 54.6% of total assets in 2024, an increase from 37.9% in 2007.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2024, up from 5.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 13.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 20.1% of total assets.
Zhejiang Jolly Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Jolly Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
CSPC Pharmaceutical Group Limited
F:CVG
|
Germany | €46.00 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥1.60 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥1.60 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.55 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
Zhejiang Jolly Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.86 | 1.93 | 1.61 |
| Quick Ratio | 1.48 | 1.52 | 1.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.10 Billion | CN¥1.09 Billion | CN¥366.33 Million |
Zhejiang Jolly Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Jolly Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.73 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 10.1% |
| Total Assets | CN¥3.99 Billion |
| Market Capitalization | $1.56 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Jolly Pharmaceutical Co Ltd's assets below their book value (0.39x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Zhejiang Jolly Pharmaceutical Co Ltd's assets grew by 10.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zhejiang Jolly Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual total assets of Zhejiang Jolly Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.99 Billion ≈ $584.15 Million |
+10.06% |
| 2023-12-31 | CN¥3.63 Billion ≈ $530.75 Million |
-0.33% |
| 2022-12-31 | CN¥3.64 Billion ≈ $532.52 Million |
+32.40% |
| 2021-12-31 | CN¥2.75 Billion ≈ $402.20 Million |
+11.28% |
| 2020-12-31 | CN¥2.47 Billion ≈ $361.42 Million |
+20.44% |
| 2019-12-31 | CN¥2.05 Billion ≈ $300.07 Million |
-2.99% |
| 2018-12-31 | CN¥2.11 Billion ≈ $309.32 Million |
-1.79% |
| 2017-12-31 | CN¥2.15 Billion ≈ $314.97 Million |
+5.62% |
| 2016-12-31 | CN¥2.04 Billion ≈ $298.20 Million |
+10.12% |
| 2015-12-31 | CN¥1.85 Billion ≈ $270.79 Million |
+56.62% |
| 2014-12-31 | CN¥1.18 Billion ≈ $172.89 Million |
+25.44% |
| 2013-12-31 | CN¥941.90 Million ≈ $137.83 Million |
+8.99% |
| 2012-12-31 | CN¥864.19 Million ≈ $126.46 Million |
+2.40% |
| 2011-12-31 | CN¥843.91 Million ≈ $123.49 Million |
+142.05% |
| 2010-12-31 | CN¥348.64 Million ≈ $51.02 Million |
+17.09% |
| 2009-12-31 | CN¥297.77 Million ≈ $43.57 Million |
+6.39% |
| 2008-12-31 | CN¥279.87 Million ≈ $40.95 Million |
+11.39% |
| 2007-12-31 | CN¥251.25 Million ≈ $36.77 Million |
-- |
About Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. It offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kid… Read more